Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADE-MI
NCT06169371Phase 4Recruiting
- Sponsor
- University of Illinois Chicago
- Start
- Dec 2023
- Primary completion
- Nov 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of abemaciclib in breast cancer, sponsored by University of Illinois Chicago. Started Dec 2023; status: recruiting.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06169371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06169371.